Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Verrica Pharmaceuticals Inc. VRCA
$6.26
-$0.09 (-1.42%)
На 18:01, 12 мая 2023
+91.69%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
265342314.00000000
-
week52high
8.70
-
week52low
1.77
-
Revenue
9032000
-
P/E TTM
-10
-
Beta
1.99631800
-
EPS
-0.72000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 31 мая 2022 г. |
| RBC Capital | Sector Perform | Outperform | 25 мая 2022 г. |
| Brookline Capital | Buy | 10 мар 2022 г. | |
| Needham | Buy | Buy | 03 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 22 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hayes Christopher G. | A | 15714 | 7500 | 11 июл 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 5038983 | 1428571 | 05 июл 2022 г. |
| Manning Paul B | A | 13651128 | 4761904 | 05 июл 2022 г. |
| Stalfort John A III | A | 700205 | 238095 | 05 июл 2022 г. |
| Goldenberg Gary | A | 23809 | 23809 | 05 июл 2022 г. |
| White Ted | A | 29466 | 23809 | 05 июл 2022 г. |
| Hayes Christopher G. | A | 8214 | 5714 | 05 июл 2022 г. |
| Ballaron Craig | A | 10384 | 10384 | 09 июн 2022 г. |
| Nguyen Diem | A | 10384 | 10384 | 09 июн 2022 г. |
| Eichenfield Lawrence | A | 10384 | 10384 | 09 июн 2022 г. |
Новостная лента
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
10 мая 2023 г. в 07:30
WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held at the InterContinental New York Barclay Hotel from May 16-17, 2023.
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
InvestorPlace
26 апр 2023 г. в 20:01
Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
31 авг 2022 г. в 16:30
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET.